ZA201501350B - N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as a2a agonists - Google Patents
N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as a2a agonistsInfo
- Publication number
- ZA201501350B ZA201501350B ZA2015/01350A ZA201501350A ZA201501350B ZA 201501350 B ZA201501350 B ZA 201501350B ZA 2015/01350 A ZA2015/01350 A ZA 2015/01350A ZA 201501350 A ZA201501350 A ZA 201501350A ZA 201501350 B ZA201501350 B ZA 201501350B
- Authority
- ZA
- South Africa
- Prior art keywords
- uronamides
- alkynyladenosine
- disubstituted
- agonists
- alkyl
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Transplantation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261678605P | 2012-08-01 | 2012-08-01 | |
| US201361787188P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/053053 WO2014022577A1 (en) | 2012-08-01 | 2013-07-31 | N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as a2a agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201501350B true ZA201501350B (en) | 2016-12-21 |
Family
ID=50025663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2015/01350A ZA201501350B (en) | 2012-08-01 | 2015-02-27 | N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as a2a agonists |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9067963B2 (en_2) |
| EP (1) | EP2879683B1 (en_2) |
| JP (1) | JP6545618B2 (en_2) |
| KR (1) | KR20150036767A (en_2) |
| CN (1) | CN104582709A (en_2) |
| AU (1) | AU2013296420B2 (en_2) |
| BR (1) | BR112015002249A2 (en_2) |
| CA (1) | CA2880040A1 (en_2) |
| EA (1) | EA027174B1 (en_2) |
| IL (1) | IL236986A (en_2) |
| IN (1) | IN2015DN00538A (en_2) |
| MX (1) | MX367879B (en_2) |
| NZ (1) | NZ703992A (en_2) |
| WO (1) | WO2014022577A1 (en_2) |
| ZA (1) | ZA201501350B (en_2) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2336117A1 (en) | 2005-05-26 | 2011-06-22 | Neuron Systems, Inc | Heterocyclic compounds for treating retinal diseases |
| WO2011072141A1 (en) | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
| US9822141B2 (en) * | 2012-08-01 | 2017-11-21 | Lewis And Clark Pharmaceuticals, Inc. | N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists |
| HK1217439A1 (zh) | 2013-01-23 | 2017-01-13 | Aldeyra Therapeutics, Inc. | 與毒性醛相關的疾病和治療 |
| EP4400106A1 (en) | 2015-08-21 | 2024-07-17 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
| AU2017264697A1 (en) | 2016-05-09 | 2018-11-22 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
| CN110431130A (zh) | 2017-03-16 | 2019-11-08 | 奥尔德拉医疗公司 | 多晶型化合物和其用途 |
| MX2020003425A (es) | 2017-10-10 | 2020-07-29 | Aldeyra Therapeutics Inc | Tratamiento de trastornos inflamatorios. |
| AU2019319740A1 (en) | 2018-08-06 | 2021-03-25 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| EP3962894A4 (en) | 2019-05-02 | 2023-01-11 | Aldeyra Therapeutics, Inc. | POLYMORPHIC COMPOUNDS AND USES THEREOF |
| WO2020223717A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| US20220332750A1 (en) * | 2019-06-21 | 2022-10-20 | Academy Of Military Medical Sciences | Adenosine compound, its pharmaceutically acceptable salt or its stereoisomer and use thereof |
| EP4149470A4 (en) | 2020-05-13 | 2024-04-24 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| WO2024258897A1 (en) | 2023-06-13 | 2024-12-19 | Dem Biopharma, Inc. | Alkoxypyridinyl and related compounds and their use in therapy |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| JPS6299395A (ja) | 1985-10-25 | 1987-05-08 | Yamasa Shoyu Co Ltd | ２−アルキニルアデノシンおよび抗高血圧剤 |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| JPH02104783A (ja) * | 1988-10-11 | 1990-04-17 | Kanai Hiroyuki | スチールコードおよびタイヤ |
| EP0444196B1 (en) | 1988-11-15 | 1994-06-08 | Yamasa Shoyu Kabushiki Kaisha | Agent for treatment and prophylaxis of ischemic disease of heart or brain |
| WO1990015812A1 (fr) | 1989-06-20 | 1990-12-27 | Yamasa Shoyu Kabushiki Kaisha | Intermediaire de synthese de 2-alkynyladenosine, production de cet intermediaire, production de 2-alkynyladenosine avec cet intermediaire et derive stable de 2-alkynyladenosine |
| US5189027A (en) | 1990-11-30 | 1993-02-23 | Yamasa Shoyu Kabushiki Kaisha | 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases |
| JP3025557B2 (ja) * | 1991-06-28 | 2000-03-27 | ヤマサ醤油株式会社 | ２‐アルキニルアデノシン誘導体 |
| IT1254915B (it) | 1992-04-24 | 1995-10-11 | Gloria Cristalli | Derivati di adenosina ad attivita' a2 agonista |
| JP2002173427A (ja) | 1998-09-01 | 2002-06-21 | Yamasa Shoyu Co Ltd | 眼疾患治療用医薬組成物 |
| US6322771B1 (en) | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
| IL151452A0 (en) | 2000-03-23 | 2003-04-10 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| NZ545787A (en) | 2001-10-01 | 2007-12-21 | Univ Virginia | 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof |
| WO2004022573A2 (en) | 2002-09-09 | 2004-03-18 | Cv Therapeutics, Inc. | Adenosine a3 receptor agonists |
| NZ553288A (en) | 2004-08-02 | 2010-12-24 | Univ Virginia | 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity |
| WO2006091896A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Pyridyl substituted xanthines |
| US8178509B2 (en) * | 2006-02-10 | 2012-05-15 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
| EP2066685B1 (en) * | 2006-06-27 | 2011-03-02 | CBT Development Limited | Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists |
| US20080312160A1 (en) * | 2007-04-09 | 2008-12-18 | Guerrant Richard L | Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist |
| ES2537959T3 (es) | 2007-05-17 | 2015-06-16 | Gilead Sciences, Inc. | Proceso para preparar un agonista de receptor de adenosin-A2A y sus polimorfos |
| US8293720B2 (en) | 2007-12-20 | 2012-10-23 | Dogwood Pharmaceuticals, Inc. | Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
| US8058259B2 (en) | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
| WO2011002917A1 (en) * | 2009-06-30 | 2011-01-06 | Pgxhealth, Llc | Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as a2a r agonists |
-
2013
- 2013-07-31 WO PCT/US2013/053053 patent/WO2014022577A1/en active Application Filing
- 2013-07-31 BR BR112015002249A patent/BR112015002249A2/pt not_active Application Discontinuation
- 2013-07-31 AU AU2013296420A patent/AU2013296420B2/en not_active Ceased
- 2013-07-31 US US13/956,111 patent/US9067963B2/en not_active Expired - Fee Related
- 2013-07-31 CA CA2880040A patent/CA2880040A1/en not_active Abandoned
- 2013-07-31 CN CN201380043401.9A patent/CN104582709A/zh active Pending
- 2013-07-31 NZ NZ703992A patent/NZ703992A/en not_active IP Right Cessation
- 2013-07-31 MX MX2015001370A patent/MX367879B/es active IP Right Grant
- 2013-07-31 KR KR20157004901A patent/KR20150036767A/ko not_active Ceased
- 2013-07-31 EA EA201590205A patent/EA027174B1/ru not_active IP Right Cessation
- 2013-07-31 EP EP13825985.8A patent/EP2879683B1/en active Active
- 2013-07-31 JP JP2015525562A patent/JP6545618B2/ja not_active Expired - Fee Related
- 2013-07-31 IN IN538DEN2015 patent/IN2015DN00538A/en unknown
-
2015
- 2015-01-29 IL IL236986A patent/IL236986A/en active IP Right Grant
- 2015-02-27 ZA ZA2015/01350A patent/ZA201501350B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140037538A1 (en) | 2014-02-06 |
| IN2015DN00538A (en_2) | 2015-06-26 |
| US9067963B2 (en) | 2015-06-30 |
| NZ703992A (en) | 2018-04-27 |
| AU2013296420B2 (en) | 2017-12-07 |
| MX2015001370A (es) | 2016-04-26 |
| JP2015524440A (ja) | 2015-08-24 |
| EA201590205A1 (ru) | 2015-06-30 |
| MX367879B (es) | 2019-09-10 |
| KR20150036767A (ko) | 2015-04-07 |
| EP2879683B1 (en) | 2020-01-22 |
| WO2014022577A1 (en) | 2014-02-06 |
| IL236986A (en) | 2017-06-29 |
| CA2880040A1 (en) | 2014-02-06 |
| AU2013296420A1 (en) | 2015-02-12 |
| EP2879683A4 (en) | 2016-04-20 |
| BR112015002249A2 (pt) | 2017-07-04 |
| EP2879683A1 (en) | 2015-06-10 |
| EA027174B1 (ru) | 2017-06-30 |
| JP6545618B2 (ja) | 2019-07-17 |
| CN104582709A (zh) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201501350B (en) | N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as a2a agonists | |
| ZA201501009B (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| PL2877467T3 (pl) | 2-(azaindolo-2-ylo)benzoimidazole jako inhibitory pad4 | |
| ZA201407632B (en) | Triazolone compounds as mpges-1 inhibitors | |
| IL239193A0 (en) | New Benzimidazole Derivatives as Kinase Inhibitors | |
| GB2507645B (en) | Collet | |
| DK2800476T3 (da) | Fremgangsmåde til fodring | |
| SG11201500973WA (en) | Amino-quinolines as kinase inhibitors | |
| PT2858986T (pt) | Derivados de piperidina como agonistas de gpr119 | |
| IL239536A0 (en) | A structure for maintaining tools | |
| ZA201500809B (en) | Antitrichophytosis solution for external use | |
| SG11201403518QA (en) | Safety cabinet for keeping animal | |
| ZA201404888B (en) | Drill chuck isolator | |
| EP2875885A4 (en) | NOVEL DRILLING CHUCK | |
| GB201209007D0 (en) | Log holder | |
| EP2887888A4 (en) | CAROTTAGE TOOL | |
| GB2507820B (en) | Humane slaughter tool | |
| GB201308875D0 (en) | Method for increasing dipole work | |
| GB201306904D0 (en) | Method for increasing dipole work | |
| AU348805S (en) | Chisel holder | |
| GB201216854D0 (en) | Agonist | |
| GB201220811D0 (en) | Torna | |
| GB201216674D0 (en) | Holder | |
| GB201223501D0 (en) | Gripcut tool | |
| GB201218101D0 (en) | Tool |